1
|
López-Álvarez GS, Wojdacz TK, García-Cuellar CM, Monroy-Ramírez HC, Rodríguez-Segura MA, Pacheco-Rivera RA, Valencia-Antúnez CA, Cervantes-Anaya N, Soto-Reyes E, Vásquez-Garzón VR, Sánchez-Pérez Y, Villa-Treviño S. Gene silencing of Nox4 by CpG island methylation during hepatocarcinogenesis in rats. Biol Open 2017; 6:59-70. [PMID: 27895046 PMCID: PMC5278421 DOI: 10.1242/bio.020370] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The association between the downregulation of genes and DNA methylation in their CpG islands has been extensively studied as a mechanism that favors carcinogenesis. The objective of this study was to analyze the methylation of a set of genes selected based on their microarray expression profiles during the process of hepatocarcinogenesis. Rats were euthanized at: 24 h, 7, 11, 16 and 30 days and 5, 9, 12 and 18 months post-treatment. We evaluated the methylation status in the CpG islands of four deregulated genes (Casp3, Cldn1, Pex11a and Nox4) using methylation-sensitive high-resolution melting technology for the samples obtained from different stages of hepatocarcinogenesis. We did not observe methylation in Casp3, Cldn1 or Pex11a. However, Nox4 exhibited altered methylation patterns, reaching a maximum of 10%, even during the early stages of hepatocarcinogenesis. We observed downregulation of mRNA and protein of Nox4 (97.5% and 40%, respectively) after the first carcinogenic stimulus relative to the untreated samples. Our results suggest that Nox4 downregulation is associated with DNA methylation of the CpG island in its promoter. We propose that methylation is a mechanism that can silence the expression of Nox4, which could contribute to the acquisition of neoplastic characteristics during hepatocarcinogenesis in rats. Summary: Many genes downregulated by DNA methylation are tumor suppressor genes. In the present study, DNA methylation of Nox4 is observed, with implications for Nox4 as a potential therapeutic target for liver or other cancers.
Collapse
Affiliation(s)
- Guadalupe S López-Álvarez
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| | - Tomasz K Wojdacz
- Aarhus Institute of Advanced Studies and Department of Biomedicine, Bartholins Allé 6 Building, 1242, 8000 Aarhus C, Denmark
| | - Claudia M García-Cuellar
- Instituto Nacional de Cancerología (INCan), Subdirección de Investigación Básica, San Fernando No. 22, Tlalpan, CDMX CP 14080, México
| | - Hugo C Monroy-Ramírez
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| | - Miguel A Rodríguez-Segura
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| | - Ruth A Pacheco-Rivera
- Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas-IPN, Carpio y Plan de Ayala S/N, Col. Casco de Santo Tomas, CDMX CP 11340, México
| | - Carlos A Valencia-Antúnez
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| | - Nancy Cervantes-Anaya
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| | - Ernesto Soto-Reyes
- Instituto Nacional de Cancerología (INCan), Subdirección de Investigación Básica, San Fernando No. 22, Tlalpan, CDMX CP 14080, México
| | - Verónica R Vásquez-Garzón
- CONACYT, Facultad de Medicina y Cirugía, Universidad Autónoma "Benito Juárez" de Oaxaca, Ex-Hacienda de Aguilera S/N Carretera a San Felipe del Agua, Oaxaca, Oax., CP 68020, México
| | - Yesennia Sánchez-Pérez
- Instituto Nacional de Cancerología (INCan), Subdirección de Investigación Básica, San Fernando No. 22, Tlalpan, CDMX CP 14080, México
| | - Saúl Villa-Treviño
- Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV), Av. IPN No. 2508 Col. San Pedro Zacatenco, CDMX CP 07360, México
| |
Collapse
|
2
|
Gutiérrez-Vidal R, Vega-Badillo J, Reyes-Fermín LM, Hernández-Pérez HA, Sánchez-Muñoz F, López-Álvarez GS, Larrieta-Carrasco E, Fernández-Silva I, Méndez-Sánchez N, Tovar AR, Villamil-Ramírez H, Mejía-Domínguez AM, Villarreal-Molina T, Hernández-Pando R, Campos-Pérez F, Aguilar-Salinas CA, Canizales-Quinteros S. SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women. Ann Hepatol 2016; 14:666-74. [PMID: 26256895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND AIMS Secreted frizzled-related protein 5 (SFRP5) was recently described as a new adipokine protective for hepatic steatosis and other obesity-related complications in the mouse model. To date, SFRP5 expression in non-alcoholic fatty liver disease (NAFLD) has not been fully assessed in humans. We measured circulating SFRP5 levels and its expression in liver and adipose tissue, and evaluated its association with NAFLD in morbidly obese women. MATERIAL AND METHODS Fifty-four morbidly obese women undergoing bariatric surgery were included in the study. Liver biopsies were used for histology and hepatic triglyceride content quantification. Circulating SFRP5 levels were measured through enzyme-linked immunoabsorbent assay, and SFRP5 expression was performed in hepatic and adipose tissue (subcutaneous and visceral). RESULTS Although circulating SFRP5 levels showed a tendency to decrease with NAFLD progression, no significant differences were observed among non-alcoholic steatosis, steatohepatitis, and control subjects. Hepatic SFRP5 expression showed a negative correlation with hepatic triglyceride content (r = -0.349, P = 0.016 for mRNA and r = -0.291, P = 0.040 for SRFP5 protein) and ALT serum levels (r = -0.437, P = 0.001 for SRFP5 protein). In addition, hepatic SFRP5 protein levels were significantly lower in NASH than in control subjects (P = 0.006). CONCLUSION This is the first study reporting an association of hepatic SFRP5 expression with NAFLD in humans.
Collapse
Affiliation(s)
- Roxana Gutiérrez-Vidal
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| | - Joel Vega-Badillo
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| | - Laura M Reyes-Fermín
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| | - Hugo A Hernández-Pérez
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| | - Fausto Sánchez-Muñoz
- Departamento de Inmunología, Instituto Nacional de Cardiología Ignacio Chávez (INCICh), Mexico City, Mexico
| | - Guadalupe S López-Álvarez
- Departamento de Biología Celular, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional Zacatenco (CINVESTAV), Mexico City, Mexico
| | - Elena Larrieta-Carrasco
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico
| | - Itzel Fernández-Silva
- Clínica Integral de Cirugía para la Obesidad y Enfermedades Metabólicas, Hospital General Dr. Rubén Leñero, Mexico City, Mexico
| | | | - Armando R Tovar
- Departamento Fisiología de la Nutrición, INCMNSZ, Mexico City, Mexico
| | - Hugo Villamil-Ramírez
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| | | | | | | | - Francisco Campos-Pérez
- Clínica Integral de Cirugía para la Obesidad y Enfermedades Metabólicas, Hospital General Dr. Rubén Leñero, Mexico City, Mexico
| | | | - Samuel Canizales-Quinteros
- Unidad de Genómica de Poblaciones Aplicada a la Salud. Facultad de Química, Universidad Nacional Autónoma de México. Instituto Nacional de Medicina Genómica (INMEGEN). Mexico City, Mexico
| |
Collapse
|